Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021
Open Access
- 31 August 2022
- journal article
- research article
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (12) , 2438-2445
Abstract
No abstract availableKeywords
Funding Information
- National Taiwan University (109F004T)
- Ministry of Science and Technology, Taiwan
This publication has 21 references indexed in Scilit:
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 MonthsNew England Journal of Medicine, 2021
- Covid-19 Breakthrough Infections in Vaccinated Health Care WorkersNew England Journal of Medicine, 2021
- Epidemic trend of COVID-19 in Taiwan, May to June 2021Journal of the Formosan Medical Association, 2021
- The Potential Declining Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) on Inoculators With Nonsteroidal Anti-inflammatory Drug (NSAID) IntakeClinical Infectious Diseases, 2021
- Vaccine efficacy against COVID-19: A foresight on the host-associated factorsJournal of the Formosan Medical Association, 2021
- Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 InfectionJournal of Virology, 2021
- Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for CancerNew England Journal of Medicine, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020
- COVID-19 in Immunocompromised Hosts: What We Know So FarClinical Infectious Diseases, 2020
- Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic CellsImmune Network, 2010